Apellis Pharmaceuticals, Inc.
Combination therapy for C3 inhibition
Last updated:
Abstract:
In some aspects, the present invention provides certain combination therapies comprising compstatin analogs.
Status:
Grant
Type:
Utility
Filling date:
16 Oct 2017
Issue date:
24 May 2022